Silverback falls on hard times, axing lead I/O candidates and laying off more than a fourth of staff - Endpoints News

Silverback Therapeutics became the latest biotech to undertake a “strategic realignment” Thursday, revealing it would drop its two lead cancer programs — sending it back to the preclinical drawing board — and lay off more than a quarter of its staff. The Seat…

Silverback Therapeutics became the latest biotech to undertake a strategic realignment Thursday, revealing it would drop its two lead cancer programs sending it back to the preclinical drawing board … [+2980 chars]

full article...